论文部分内容阅读
目的 评价美施康定对癌性疼痛的治疗作用。方法 对 6 8例中重度癌症患者应用美施康定片治疗 ,初始剂量由 6 0 mg开始 ,观察 1～ 2天后若疼痛无缓解即增加剂量 ,直至疼痛缓解。如经化放疗后疼痛减轻则应减量。结果 6 8例癌痛患者中 ,显效 40例 (5 9% ) ,有效 2 4例 (35 % ) ,无效 4例 (6 % ) ,总有效率 94%。药物最小日剂量为 30 mg,最大日剂量为 2 40 m g,副作用主要是便秘和恶心 ,仅须对症处理。结论 美施康定作为控制中重度癌痛的药物 ,镇痛效果满意 ,不良反应小 ,服用方便 ,对慢性癌性疼痛应作为首选药物 ,值得临床推广应用。
Objective To evaluate the therapeutic effect of metstaining on cancer pain. Methods Sixty-eight patients with moderate-to-severe cancer were treated with methopin tablets. The initial dose was started from 60 mg. After 1 to 2 days, if the pain was not relieved, the dose was increased until the pain was relieved. If the pain relief after chemotherapy and radiotherapy should be reduced. Results Of the 68 patients with cancer pain, 40 (59%) were markedly effective, 24 (35.5%) effective, 4 (6%) ineffective, and the total effective rate was 94%. The minimum daily dose of the drug is 30 mg, and the maximum daily dose is 2 40 m g. The major side effects are constipation and nausea, and only symptomatic treatment is required. Conclusion As a drug for controlling moderate-severe cancer pain, Methiconidine has satisfactory analgesic effect, small adverse reactions and convenient administration. It should be the first choice for chronic cancer pain and it is worthy of clinical application.